| 2025-02-04 |
复牌提示：
2025-02-03 14:11:36 停牌，复牌日期 2025-02-04 16:50:00
|
| 2024-12-13 |
股东大会：
将于2025-01-14召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the accompanying proxy statement by the voting groups set forth below; Three directors to be elected by the holders of our common stock, no par value per share (the “common stock”), voting separately as a single class;One director to be elected by the holders of our 12.5% Series B Cumulative Redeemable Preferred Shares, no par value per share (the “Series B Preferred Stock”), voting separately as a single class.
2.To ratify the appointment of Cherry Bekaert, LLP as our independent registered public accounting firm for the year ending December 31, 2024, by the holders of our common stock voting separately as a single class;
3.To transact such other business as may properly come before the 2024 Annual Meeting of Shareholders and any adjournments or postponements thereof.
|
| 2024-12-13 |
详情>>
股本变动：
变动后总股本187.92万股
|
| 2024-11-19 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.42美元,归母净利润-265万美元,同比去年增长-106.67%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.91美元,归母净利润-166.8万美元,同比去年增长-104.1%
|
| 2024-06-19 |
详情>>
内部人交易：
O'sullivan Paul Jason等共交易2笔
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.52美元,归母净利润-96.2万美元,同比去年增长77.32%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益21.05美元,归母净利润3950.70万美元,同比去年增长349.04%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益21.18美元,归母净利润3974.50万美元,同比去年增长449.53%
|
| 2023-10-04 |
股东大会：
将于2023-11-16召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the accompanying proxy statement (Proposal 1);
2.To approve the Regional Health Properties, Inc. 2023 Omnibus Incentive Compensation Plan (Proposal 2);
3.To ratify the appointment of Cherry Bekaert, LLP as our independent registered public accounting firm for the year ending December 31, 2023 (Proposal 3);
4.To transact such other business as may properly come before the 2023 Annual Meeting of Shareholders and any adjournments or postponements thereof.
|
| 2023-08-18 |
详情>>
业绩披露：
2023年中报每股收益21.74美元,归母净利润4071.90万美元,同比去年增长565.36%
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-2.28美元,归母净利润-424.1万美元,同比去年增长18.08%
|
| 2023-04-14 |
详情>>
业绩披露：
2022年年报每股收益-8.93美元,归母净利润-1586.4万美元,同比去年增长-55.85%
|
| 2022-12-30 |
股东大会：
将于2023-02-14召开股东大会
会议内容 ▼▲
- 1.To elect the six director nominees named in the accompanying proxy statement (Proposal 1);
2.To consider an advisory vote on executive compensation (“Say-on-Pay”) (Proposal 2);
3.To ratify the appointment of Cherry Bekaert, LLP as our independent registered public accounting firm for the year ending December 31, 2022 (Proposal 3);
4.To transact such other business as may properly come before the 2022 Annual Meeting of Shareholders and any adjournments or postponements thereof.
|
| 2022-11-22 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-6.4美元,归母净利润-1137.1万美元,同比去年增长-56.43%
|
| 2022-08-23 |
详情>>
业绩披露：
2022年中报每股收益-4.93美元,归母净利润-875万美元,同比去年增长-75.7%
|
| 2021-10-22 |
股东大会：
将于2021-12-02召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the accompanying proxy statement to serve until our 2022 Annual Meeting of Shareholders and until their successors are elected and qualified, or until their earlier death, resignation or removal (Proposal 1);
2.To ratify the appointment of Cherry Bekaert, LLP as our independent registered public accounting firm for the year ending December 31, 2021 (Proposal 2);
3.To transact such other business as may properly come before the 2021 Annual Meeting of Shareholders and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-11-05 |
股东大会：
将于2020-12-16召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the accompanying proxy statement to serve until our 2021 Annual Meeting of Shareholders and until their successors are elected and qualified, or until their earlier death, resignation or removal (Proposal 1);
2.To approve the Regional Health Properties, Inc. 2020 Equity Incentive Plan (Proposal 2);
3.To ratify the appointment of Cherry Bekaert, LLP as our independent registered public accounting firm for the year ending December 31, 2020 (Proposal 3);
4.To transact such other business as may properly come before the 2020 Annual Meeting of Shareholders and any adjournments or postponements thereof.
|
| 2019-11-20 |
股东大会：
将于2019-12-23召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the accompanying proxy statement to serve until our 2020 Annual Meeting of Shareholders (Proposal 1);
2.To consider an advisory vote on executive compensation (“Say-on-Pay”) (Proposal 2);
3.To consider an advisory vote to determine shareholder preference on the frequency of the Say-on-Pay vote (“Say-When-on-Pay”) (Proposal 3);
4.To ratify the appointment of Cherry Bekaert, LLP as our independent registered public accounting firm for the year ending December 31, 2019 (Proposal 4);
5.To transact such other business as may properly come before the 2019 Annual Meeting and any adjournments thereof.
|
| 2019-01-02 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2018-11-09 |
股东大会：
将于2018-12-27召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the accompanying proxy statement to serve until Regional’s 2019 Annual Meeting of Shareholders (Proposal 1);
2.To approve an amendment to Regional’s Articles of Incorporation to effect a reverse stock split of Regional’s common stock at a ratio of between one-for-six and one-for-twelve, as determined by the Board of Directors in its sole discretion (Proposal 2);
3.To ratify the appointment of Cherry Bekaert, LLP as Regional’s independent registered public accounting firm for the year ending December 31, 2018 (Proposal 3);
4.To adjourn the 2018 Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the 2018 Annual Meeting to approve Proposal 2.
|